IFNA1 and hepatocellular carcinoma: In patients receiving PEG-IFN-alfa−2b plus ribavirin treatment11 cumulative survival rates among HCV-related HCC patients were 100% after 1 year and 90.2% after 3 years in the IFN-treated subjects compared to 96.0% and 61.2% in the non-treated controls11.